Barni Sandro, Gascòn Pere, Petrelli Fausto, García-Erce José Antonio, Pedrazzoli Paolo, Rosti Giovanni, Giordano Giulio, Mafodda Antonio, Múñoz Manuel
a Oncology Department , Medical Oncology Unit , Treviglio , Italy.
b Division of Medical Oncology , Hospital Clinic, University of Barcelona , Barcelona , Spain.
Expert Rev Hematol. 2017 Aug;10(8):685-695. doi: 10.1080/17474086.2017.1343140. Epub 2017 Jul 3.
Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficiency anemia and cancer-associated anemia are usually treated with supportive therapies. Optimal management of these conditions are discussed in this perspective paper. Areas covered: A position paper discussing a number of hot topics on anemia in cancer patients is presented. The main areas covered by experts in the field are: definitions, prevalence and consequences of anemia and iron deficiency, incidence of anemia resulting from targeted therapies, importance of anemia diagnosis and monitoring, evaluation of iron status before and during treatment, role of transfusions and erythropoiesis-stimulating agents, management of iron deficiency with or without anemia, parenteral iron supplementation, role of new oral iron formulations, safety and cost issues regarding different iron compounds and administration routes. Expert commentary: Despite the availability of newer therapeutic options for its management, anemia still represents a major complication of treatment in cancer patients (surgery, chemotherapy, radiotherapy, targeted therapies), aggravating physical impairment, and negatively affecting general outcome. The view expressed by the panelists, attendees of the 4th Mediterranean Course on Iron Anemia, summarizes what they consider optimal clinical practice for screening, diagnosis, treatment and monitoring of iron deficiency and anemia in cancer patients.
铁代谢紊乱在肿瘤血液学临床实践中很常见。缺铁性贫血和癌症相关性贫血通常采用支持性疗法进行治疗。本文从这一角度探讨了这些病症的最佳管理方法。涵盖领域：本文发表了一篇立场文件，讨论了癌症患者贫血的一些热点话题。该领域专家涵盖的主要领域包括：贫血和缺铁的定义、患病率及后果、靶向治疗导致贫血的发生率、贫血诊断和监测的重要性、治疗前和治疗期间铁状态的评估、输血和促红细胞生成素的作用、有无贫血时缺铁的管理、胃肠外补铁、新型口服铁制剂的作用、不同铁化合物和给药途径的安全性及成本问题。专家评论：尽管有了更新的治疗选择，但贫血仍然是癌症患者治疗（手术、化疗、放疗、靶向治疗）的主要并发症，会加重身体损伤，并对总体预后产生负面影响。第四届地中海缺铁性贫血课程的与会专家小组表达的观点总结了他们认为癌症患者缺铁和贫血筛查、诊断、治疗及监测的最佳临床实践。
